# Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

> **NCT03299244** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 637 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Chronic Kidney Disease

## Interventions

- **DRUG:** Etelcalcetide
- **DRUG:** Cinacalcet

## Key facts

- **NCT ID:** NCT03299244
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2020-04-08
- **Final completion:** 2020-04-08
- **Target enrollment:** 637 (ACTUAL)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299244, "Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03299244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*